Felycin®-CA1 is the First and Only Drug FDA Conditionally Approved for the Management of Ventricular Hypertrophy in Cats
PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional approval from the FDA for Felycin®-CA1 (sirolimus delayed-release tablets) sold under the PRN Pharmacal brand of its affiliated company Pegasus, today announced the product is now available via licensed veterinarians nationwide. PBI-Gordon Companies, Inc. confirms that Felycin®-CA1 is the only drug currently legally marketed under conditional approval from the Food and Drug Administration (FDA) for the management HCM in cats.
Unraveling the Genetics of Feline Hypertrophic Cardiomyopathy: Insights from a Multiomics Study of 138 Cats
This article reviews a groundbreaking multiomics study investigating the genetics of feline hypertrophic cardiomyopathy (HCM) in 138 domestic cats. It discusses how whole genome sequencing and RNA transcriptomics revealed rare genetic variants and distinct molecular signatures linked to HCM. The findings highlight the complexity of feline HCM genetics and point to future opportunities for biomarker discovery and targeted therapies. Keywords include feline HCM genetics, RNA sequencing in cats, inherited cat heart disease, and veterinary precision medicine.
Felycin®-CA1 is the First and Only Drug FDA Conditionally Approved for the Management of Ventricular Hypertrophy in Cats
PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional approval from the FDA for Felycin®-CA1 (sirolimus delayed-release tablets) sold under the PRN Pharmacal brand of its affiliated company Pegasus, today announced the product is now available via licensed veterinarians nationwide. PBI-Gordon Companies, Inc. confirms that Felycin®-CA1 is the only drug currently legally marketed under conditional approval from the Food and Drug Administration (FDA) for the management HCM in cats.